UK medtech needs to seize moment and make most of OLS
This article was originally published in Clinica
This month’s unveiling of the blueprint for the UK Office for Lifesciences (OLS) will be looked back on as a pivotal moment for the UK healthcare sector, writes Clinica principal analyst Ashley Yeo.
You may also be interested in...
The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.
The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.
Forum officially unveiled on 19 February to represent growing band of organizations designated against the UKCA mark.